Dr. Reddy's Laboratories share news, announcements and annual reports
NSE: DRREDDYBSE: 500124Pharmaceuticals & BiotechnologyMid Cap
Dr. Reddy's Laboratories Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Aug 1986 on BSE, May 2003 on NSE
Last close ₹1,345.00up ₹9.60 (0.72%)BSE ₹1,338.50
Share price at the NSE close on 29 Oct 2026. Previous close ₹1,335.40.
29 Oct: open ₹1,343.50, high ₹1,352.80, low ₹1,336.10
52-week range of traded prices to 29 Oct 2026
₹1,101.00Low, 23 Jul 2026₹1,414.90High, 29 Jun 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,12,264 Cr104th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 40.10
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.89
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.59%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 7.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 6.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.15
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 20,20,77261.4% delivered
Dr. Reddy's Laboratories board and management
47 filed, newest first.
Oct 2026
Aug 2026
Jul 2026
May 2026
Mar 2026
Feb 2026
Nov 2025
Sep 2025
Jul 2025
May 2025
May 2024
Apr 2024
Jan 2024
Dec 2023
Sep 2023
May 2023
Jan 2023
Aug 2022
Jul 2022
May 2022
Mar 2022
Jan 2022
Oct 2021
May 2021
Jul 2019
Mar 2019
Jan 2019
Oct 2018
Jun 2018
Jun 2016
May 2016
Feb 2012
3 Feb · Management
Dr. Reddy'S Laboratories Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on February 03, 2012 based on the recommendation of the Nomination, Governance and Compensation Committee, has approved the re-appointment of Mr. Satish Reddy as Whole-time Director designated as Managing Director and Chief Operating Officer for the a period of 5 years, subject to the shareholders' approval.
Aug 2011
22 Aug · Management
Dr. Reddy'S Laboratories Limited has informed the Exchange that the Board of Directors of the Company at their meeting held on August 22, 2011 has appointed Mr. Sridar Iyengar as an Additional Director on the Board of Directors of the Company with effect from August 22, 2011.
Oct 2009
26 Oct · Management
Dr. Reddy'S Laboratories Ltd. has informed the Exchange that the Board of Directors of the Company at their meeting held on October 23, 2009 has appointed Dr. Ashok S Ganguly as an Additional Director on the Board of Directors of the Company with effect from October 23, 2009.
Jan 2009
20 Jan · Management
Dr. Reddy'S Laboratories Ltd. has informed the Exchange that Prof. Krishna G. Palepu, non-executive Director on the Board of Directors of the Company has resigned from his position with effect from January 20, 2009. The Board has accepted his resignation with immediate effect and appreciated his contribution to the Company.
Dec 2007
11 Dec · Management
Dr. Reddy'S Laboratories Ltd. has informed the Exchange that "Mr. Girish Tekchandani, Asst. Company Secretary has resigned and relieved from our Company with effect from December 7, 2007".
Jun 2007
5 Jun · Management
Dr. Reddy'S Laboratories Ltd. has informed the Exchange that: "The Board of Directors have appointed Ms.Kalpana Morparia as an Additional Director on the Board of the Company by way of a circular resolution dated June 05, 2007".
May 2007
18 May · Management
Dr. Reddy'S Laboratories Ltd. has informed the Exchange with respect to the Board Meeting held on May 18, 2007 that: "(1) The Board of Directors has appointed Dr. J P Moreau as Additional Director on the Board of the Company. (2) The Compensation Committee has granted 466,460 stock options including 87,500 ADR linked stock options to the employees of the Company. The shares covered by such options are 466,460. The options have been granted at a price of Rs.5 per option. The options may be exercised in a phased manner after a vesting period of 12 months but before completion of five years from the date of vesting".